MoonLake Immunotherapeutics’ (MLTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $100.00 price target on the stock. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($3.62) EPS.

A number of other analysts have also issued reports on MLTX. Wedbush reiterated an “outperform” rating and set a $73.00 price target (down from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. The Goldman Sachs Group upgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $62.00 to $82.00 in a research note on Friday, January 17th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $83.20.

MoonLake Immunotherapeutics Price Performance

NASDAQ MLTX opened at $41.76 on Thursday. The firm’s 50-day moving average is $46.49 and its two-hundred day moving average is $48.91. MoonLake Immunotherapeutics has a 12 month low of $37.55 and a 12 month high of $58.26. The stock has a market capitalization of $2.67 billion, a P/E ratio of -32.37 and a beta of 1.28.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.09). As a group, analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Institutional Trading of MoonLake Immunotherapeutics

Large investors have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of MoonLake Immunotherapeutics by 96.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,814 shares of the company’s stock worth $1,806,000 after buying an additional 17,580 shares during the period. Erste Asset Management GmbH purchased a new stake in shares of MoonLake Immunotherapeutics during the third quarter worth approximately $741,000. Barclays PLC increased its stake in shares of MoonLake Immunotherapeutics by 1,269.2% during the third quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after buying an additional 5,229 shares during the period. State Street Corp increased its stake in shares of MoonLake Immunotherapeutics by 96.2% during the third quarter. State Street Corp now owns 87,637 shares of the company’s stock worth $4,419,000 after buying an additional 42,980 shares during the period. Finally, Congress Asset Management Co. increased its stake in shares of MoonLake Immunotherapeutics by 9.5% during the fourth quarter. Congress Asset Management Co. now owns 72,993 shares of the company’s stock worth $3,953,000 after buying an additional 6,352 shares during the period. 93.85% of the stock is currently owned by hedge funds and other institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.